Home
Live Updates
Does Immunotherapy Offer Survival Gain in Older NSCLC Patients? : comparemela.com
Does Immunotherapy Offer Survival Gain in Older NSCLC Patients?
Contrary to clinical trial results, the survival benefit of checkpoint inhibitors in the real-world setting is lower among older people with NSCLC, who make up a large proportion of patients.
Related Keywords
Boston ,
Massachusetts ,
United States ,
Australia ,
New Haven ,
Connecticut ,
Sydney ,
New South Wales ,
Dana Farber Cancer Institute ,
American ,
Chee Khoon Lee ,
Caryp Gross ,
Kennethl Kehl ,
Yale School Of Medicine ,
American Society Of Clinical Oncology ,
European Society For Medical Oncology ,
Yale School ,
Medscape Medical ,
American Society ,
Clinical Oncology ,
European Society ,
Medical Oncology ,
Khoon Lee ,
George Hospital ,
Lung Cancer ,
Ung Carcinoma ,
Ancer Lung ,
Biologic Therapy ,
Cancer ,
Alignant Neoplasia ,
Arcinoma ,
Small Cell Lung Cancer ,
Immunotherapy ,
Healthcare And Medical Technology ,
Ealth And Medical Tech ,
Ealth And Med Tech ,
Ealth And Medical Technology ,
Clinical Research ,
Clinical Trials ,
Linical Studies ,
Lung ,
Social Determinants Of Health ,
Europe ,
European ,
Grant ,
Health Care Economics ,
Neconomi ,
comparemela.com © 2020. All Rights Reserved.